Friday, August 28, 2015 8:08:38 AM
A Satire
My dogs visited the NNVC Shelton facility. We saw Diwan's fleet of approximately 20 luxury cars in the parking lot. Dr. Randall Barton welcomed us. Dr. Diwan spent a few minutes with us before he had to leave to participate in an all-hands seminar. He lectured about what nanoviricides can do and the millions he raised. He insulted and joked about Seymour. Before leaving he asked Dr. Jay Tatake the second "genius" scientist in the operation to take a break from playing video games, and to give us a tour of the facility. We spent the next 45 minutes touring the entire 80,000 square foot laboratory/manufactory which Diwan hopes to acquire when NNVC goes BK.
Dr. Tatake was very thorough in explaining all the various stages of development and research. He has built an impressive knowledge of giving tours. The design and layout of the labs, work spaces and offices is impressive. I was especially impressed at the measures in place to ensure sterile conditions and pure product outcome. I have a new appreciation for the complexity they face in developing this new medical technology so I appreciate the fact that computers are everywhere directed at Google search. I left with the impression that it is not "if" but "when" BK will happen which will be before scale up completes and the product for large animal tests is shipped to BASi.
I was also impressed to see that every work space was lined with calendars delineating the tasks necessary to complete the occupant's work. i.e Coffee 9AM, 9:30AM Diwan ALL Hands Seminar, .....The new interns are being rapidly immersed in the development process.
Dr. Tatake was as excited and anxious as all of us to see Diwans years of labor come to fruition as he sails into the sunset with the millions lost by NNVC believers. I believe that in the next 18 months we will see Rawnocs faith in the science and the company vindicated.
The original
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM